141 related articles for article (PubMed ID: 6440478)
1. In vitro and in vivo antibacterial activities of MT-141, a new semisynthetic cephamycin, compared with those of five cephalosporins.
Inouye S; Goi H; Watanabe T; Hara T; Miyauchi K; Yoshida T; Kazuno Y; Kadosawa H; Hirano F; Kawaharajo K
Antimicrob Agents Chemother; 1984 Nov; 26(5):722-9. PubMed ID: 6440478
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antibacterial activity of T-1982, a new semisynthetic cephamycin antibiotic.
Tai M; Fukuoka Y; Yotsuji A; Kumano K; Takahata M; Mikami H; Yasuda T; Saikawa I; Mitsuhashi S
Antimicrob Agents Chemother; 1982 Nov; 22(5):728-34. PubMed ID: 6983861
[TBL] [Abstract][Full Text] [Related]
3. [Cefotetan, a new cephamycin antibiotic: in vitro and in vivo antibacterial activities (author's transl)].
Yano K; Suzaki K; Saito M; Toda M; Naito S; Ohmi Y
Jpn J Antibiot; 1982 Feb; 35(2):438-59. PubMed ID: 6953260
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antibacterial activity of moxalactam, an oxa-beta-lactam antibiotic.
Goto S
Rev Infect Dis; 1982; 4 Suppl():S501-10. PubMed ID: 6218559
[TBL] [Abstract][Full Text] [Related]
5. [Antibacterial activity of MT-141 against anaerobic bacteria].
Watanabe T; Hara T; Kasai T; Ishii T; Miyauchi K; Date H; Jinzaki M; Shindo H; Matsugami A; Goi H
Jpn J Antibiot; 1984 Jun; 37(6):1058-69. PubMed ID: 6092738
[TBL] [Abstract][Full Text] [Related]
6. In vitro comparison of cefotetan with five other cephalosporins against nosocomial pathogens.
Daschner FD; Goerke C; Bassler M; Just M
Chemotherapy; 1982; 28(5):351-4. PubMed ID: 6958416
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of a new cephamycin, MT-141, in compromised mice.
Kawaharajo K; Shitoh K; Niizeki M; Murata S; Sekizawa Y
J Antibiot (Tokyo); 1984 Dec; 37(12):1703-11. PubMed ID: 6441793
[TBL] [Abstract][Full Text] [Related]
8. [The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics].
Miwatani T; Takeda Y; Kotera K; Nishimura T; Takashima T; Hiromatsu K; Tabuki K; Fujimoto S; Kamiki T; Yoshizaki E; Yabuuchi E; Shimizu Y; Matsunaga K; Yamanaka K; Furuta I; Iimori M; Kodama J; Tanaka M; Maejima K; Nukina M; Takashima E; Takahashi M; Harikane O; Masutani T
Jpn J Antibiot; 1983 Feb; 36(2):260-76. PubMed ID: 6304368
[TBL] [Abstract][Full Text] [Related]
9. In-vitro and in-vivo activities of a novel cephamycin MT-141 against the Bacteroides fragilis group in comparison with six cephem antibiotics.
Kasai T; Hara T; Tamura A; Kazuno Y; Inouye S; Goto S; Kuwahara S
J Antimicrob Chemother; 1985 Jun; 15(6):701-14. PubMed ID: 3928575
[TBL] [Abstract][Full Text] [Related]
10. Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
Jorgensen JH; Crawford SA; Alexander GA
Antimicrob Agents Chemother; 1980 May; 17(5):901-4. PubMed ID: 6249198
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of moxalactam against pathogenic bacteria and its comparison with other antibiotics.
Perrymann F; Flournoy DJ; Qadri SM
Chemotherapy; 1983; 29(1):37-42. PubMed ID: 6219865
[TBL] [Abstract][Full Text] [Related]
12. Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation.
Yoshida T; Matsuura S; Mayama M; Kameda Y; Kuwahara S
Antimicrob Agents Chemother; 1980 Mar; 17(3):302-12. PubMed ID: 6448572
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of sensitivity patterns of bacteria isolated from clinical materials to the 2d generation cephamycins and cephalosporins and clinical application of these antibiotics].
Matsuo K; Uete T
Jpn J Antibiot; 1983 Jul; 36(7):1621-37. PubMed ID: 6317908
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory and bactericidal activity of cefmetazole and seven other beta-lactams against different bacterial inocula.
Esposito S; Galante D; Barba D
Chemioterapia; 1986 Apr; 5(2):101-4. PubMed ID: 3518963
[TBL] [Abstract][Full Text] [Related]
15. Comparative susceptibilities of organisms isolated in Sicily to cefotetan and other antibiotics.
Russo G; Gismondo MR; Toscano MA; Speciale AM; Nicoletti G
J Antimicrob Chemother; 1983 Jan; 11 Suppl():79-85. PubMed ID: 6573327
[TBL] [Abstract][Full Text] [Related]
16. Cefotetan: profile of in-vitro activity.
Bauernfeind A
J Antimicrob Chemother; 1983 Jan; 11 Suppl():19-29. PubMed ID: 6601656
[TBL] [Abstract][Full Text] [Related]
17. Cefoxitin and cephamycins: microbiological studies.
Stapley EO; Birnbaum J; Miller AK; Wallick H; Hendlin D; Woodruff HB
Rev Infect Dis; 1979; 1(1):73-89. PubMed ID: 400941
[TBL] [Abstract][Full Text] [Related]
18. Biological and chemotherapeutic studies on three semisynthetic cephamycins.
Uri JV; Actor P; Guarini JR; Phillips L; Pitkin D; Demarinis RM; Weisbach JA
J Antibiot (Tokyo); 1978 Jan; 31(1):82-91. PubMed ID: 627526
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of moxalactam against anaerobic bacteria.
Gilchrist MJ; Washington JA
Rev Infect Dis; 1982; 4 Suppl():S511-5. PubMed ID: 6218560
[TBL] [Abstract][Full Text] [Related]
20. In vitro comparison of three new cephalosporins: LY-127935, cefotaxime and cefoperazone.
Trager GM; White GW; Zimelis VM; Bryk DA; Panwalker AP
Chemotherapy; 1981; 27(1):34-8. PubMed ID: 6260435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
